GluBio Pharmaceutical’s GLB-002 Receives NMPA Approval for Clinical Trials in Hematological Tumors
GluBio Pharmaceutical Co., Ltd, a specialist in molecular glue targeted protein degradation (TPD) based in...
GluBio Pharmaceutical
GluBio Pharmaceutical Secures $22 Million in A+ Round Financing to Advance Protein Degradation Drugs
GluBio Pharmaceutical Co., Ltd., an emerging player in targeted protein degradation drug development, has announced...
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly...